Arrowhead Research Corporation — FY2013 Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2013. This is an annual filing, not a standalone fourth-quarter report. The filing identifies the registrant as Arrowhead Research Corporation; the request metadata uses “Arrowhead Pharmaceuticals, Inc.”
Business context
Arrowhead was a development-stage biopharmaceutical company focused on RNA interference (RNAi) therapeutics and targeted drug delivery. Its lead program, ARC-520, was in development for chronic hepatitis B (HBV). The company also pursued partner-based programs and platform collaborations, including Shire’s access to its Homing Peptide technology. It reported no marketed products and very limited revenue.
Financial performance and position
| Metric | FY2013 / September 30, 2013 | FY2012 / September 30, 2012 |
|---|---|---|
| Revenue | $0.29 million | $0.15 million |
| Operating loss | $24.6 million | $21.1 million |
| Consolidated net loss | $31.7 million | $22.1 million |
| Net loss attributable to Arrowhead | $31.1 million | $21.1 million |
| Research and development | $8.7 million reported as R&D, plus $3.6 million of R&D compensation | $5.4 million reported as R&D, plus $3.3 million of R&D compensation |
| Cash and cash equivalents | $19.1 million | $3.4 million |
| Marketable investments | $10.7 million fair value | $0.1 million |
| Current assets / current liabilities | $28.8 million / $8.7 million | $6.6 million / $5.3 million |
- Revenue was primarily amortization of upfront patent license fees; the company also recorded $115,000 of collaboration revenue in FY2013.
- Cash used in operating activities was $19.0 million, versus $15.3 million in FY2012. Investing activities used $9.5 million, mainly reflecting purchases of marketable securities; financing activities provided $44.3 million, principally from equity issuance.
- Cash plus marketable investments totaled approximately $29.8 million at year-end. Management said resources, including the subsequent financing, were expected to fund operations for at least 12 months.
- Current debt included $0.97 million of notes payable and $0.22 million of current capital lease obligations; long-term liabilities included $0.05 million of notes payable and $1.06 million of capital lease obligations. Separately, derivative liabilities were $4.1 million.
- There was no meaningful operating margin or profitability measure given the company’s development-stage status and immaterial revenue.
Changes versus the prior year
- Consolidated net loss increased to $31.7 million from $22.1 million. Higher R&D spending—especially toxicology, drug manufacturing, and ARC-520 clinical-trial costs—was partly offset by lower general and administrative expense.
- Other expense rose to $7.1 million from $1.0 million, driven mainly by a $5.3 million noncash loss from revaluation of warrant-related derivatives and a $1.0 million write-down of the Unidym-related note receivable.
- Cash rose substantially, supported by $44.5 million of net equity financing proceeds during FY2013. Common shares outstanding increased from 13.6 million to 32.5 million at year-end.
- The company recorded a $1.3 million impairment of patents after Calando terminated its Caltech license and discontinued development of the RONDEL delivery platform and CALAA-01.
Outlook, commentary and key risks
- Arrowhead completed enrollment of 36 healthy volunteers in the ARC-520 Phase 1 study. It reported no serious or severe adverse events, no identified liver, kidney, or muscle organ toxicity, and no apparent dose-related pattern in adverse events; the study was not designed to establish efficacy in HBV patients.
- Management planned to begin a Phase 2a HBV patient study in the first half of 2014 and a Phase 2b study in the second half of 2014, subject to required permissions and completion of supporting toxicology work.
- The October 11, 2013 financing raised $64 million gross and approximately $60 million net through common and convertible preferred stock. This occurred after the fiscal year-end and is not included in FY2013 cash flows.
- Management emphasized that drug development is costly and uncertain. Key risks include clinical or regulatory failure, difficulty manufacturing and supplying candidates, reliance on third-party collaborators and contractors, intellectual-property challenges, continuing losses, and potential future financing and shareholder dilution.
- No formal revenue or earnings guidance was provided. The company expected R&D and clinical costs to rise as candidates advanced.
- The filing reported effective disclosure controls and effective internal control over financial reporting as of September 30, 2013; no legal proceedings were reported.
Most important facts for investors to verify
- Reconcile the MD&A statement that net loss increased by $4.4 million with the financial statements, which show consolidated net loss rising from $22.1 million to $31.7 million—an increase of approximately $9.6 million.
- Confirm the distinction between the $31.7 million consolidated net loss and the $31.1 million loss attributable to Arrowhead shareholders.
- Check subsequent filings for ARC-520 Phase 2 trial timing, results, safety updates, and any changes to the development plan.
- Review the terms and dilution implications of the October 2013 common-stock and convertible-preferred financing, and reconcile post-financing share counts.
- Assess cash burn against available cash and investments, including the liquidity and credit risks of the corporate-bond portfolio, and monitor the $4.1 million derivative liability and its stock-price sensitivity.